In view of the translational value of CLDN6 CAR-NK cells, we preregistered it on the clinical trial website (NCT05410717) last year, hoping to recruit patients for clinical trials to evaluate the safety and preliminary efficacy of claudin-6 targeting CAR-NK cells in patients with claudin-6 positive advanced solid tumors (ovarian cancer and others). This evidence concerns the gene CLDN6 and ovarian carcinoma.